Alembic Pharma News and Updates

Name: Latest research reports of Alembic Pharmaceuticals Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Alembic Pharmaceuticals Ltd.
Rating: 3
Author: ICICI Securities Limited

Keep track of all breaking news on Alembic Pharma from all sources in a single place.

Alembic Pharmaceuticals Ltd.

11 Dec 2025

835.05

-0.31%

Alembic gets USFDA nod for generic eye infection treatment suspension

Business Standard

Alembic Pharmaceuticals Ltd on Thursday said it has received final approval from the US health regulator for its generic version of Loteprednol Etabonate and Tobramycin ophthalmic suspension used for treatment of eye infection. The approval granted by the US Food & Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) Loteprednol Etabonate and Tobramycin Ophthalmic Suspension of strength 0.5 per cent/0.3 per cent (5 mL and 10 mL), Alembic Pharmaceuticals Ltd said in a regulatory filing. Alembic was granted a Competitive Generic Therapy (CGT) designation for this application. With this approval, Alembic is eligible for 180 days of CGT exclusivity upon commercialisation, it added. The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Zylet Ophthalmic Suspension, 0.5 per cent/0.3 per cent, of Bausch & Lomb Incorporated, the company said. Loteprednol etabonate and tobramycin ophthalmic suspension, 0.5 per cent/0.3 per cent, is...

Alembic Pharmaceuticals Ltd. is trading below all available SMAs

Alembic Pharmaceuticals gets USFDA nod for generic eye infection treatment suspension

Business Line | 11 Dec 2025

Alembic Pharmaceuticals Ltd.

07 Nov 2025

835.05

-0.31%

Alembic Pharmaceuticals gets USFDA nod for generic blood cancer treatment drug

Business Line

The approval by the USFDA is for the abbreviated new drug application (ANDA) of Dasatinib Tablets of strengths 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, Alembic Pharmaceuticals said in a regulatory filing

Alembic Pharmaceutic.. has an average target of 1028.50 from 4 brokers.

Alembic Pharmaceuticals Ltd.

05 Nov 2025

835.05

-0.31%

Alembic Pharma Eyes 18-20% Ebitda Margins Driven By Production Ramp-Up, New Launches

NDTV Profit

The company is planning some high-value launches in the US market over the next 12-18 months.

Alembic Pharmaceuticals Ltd. is trading below all available SMAs

Alembic Pharmaceuticals Ltd.

05 Nov 2025, 12:00AM

835.05

-0.31%

Export drives the show; India outlook cloudy

Hold: Alembic Pharmaceuticals Ltd.

Target

ICICI Securities Limited

Alembic Pharma’s (Alembic) Q2FY26 result beat our expectations – led by formulations exports (up 25.1% YoY) while India continued to grow at a modest pace (4.9% in Q2FY26).

Alembic Pharmaceuticals Ltd. is trading below all available SMAs

Alembic Pharmaceuticals Ltd.

05 Nov 2025, 12:00AM

835.05

-0.31%

Strong Q2FY26 performance driven by US generics, margin expansion, and broad-based growth momentum

Buy: Alembic Pharmaceuticals Ltd.

Recommendation Target

Deven Choksey

Alembic Pharma is expected to maintain steady growth momentum supported by its expanding complex generics portfolio in the US, sustained traction in Ex-US markets, and a gradual recovery in the domestic formulations business.

Alembic Pharmaceuticals Ltd. is trading below all available SMAs

Alembic Pharmaceuticals Ltd.

05 Nov 2025, 12:00AM

835.05

-0.31%

Strong Q2FY26 performance driven by US generics, margin expansion, and broad-based growth momentum

Buy: Alembic Pharmaceuticals Ltd.

Deven Choksey

Alembic Pharmaceutic.. has an average target of 1028.50 from 4 brokers.

Alembic Pharmaceuticals Ltd.

04 Nov 2025, 07:49PM

835.05

-0.31%

Alembic Pharma Q2 profit rises 21% on robust US generics and API growth

Business Standard

Alembic Pharma's consolidated profit rose 21% to Rs 185 crore in Q2 FY26, led by strong performance in US generics, APIs, and international markets, with six new ANDA approvals

Alembic Pharmaceutic.. has an average target of 1028.50 from 4 brokers.

Alembic Pharmaceuticals Ltd.

04 Nov 2025, 02:48PM

835.05

-0.31%

to see Rapid results content

Alembic Pharmaceuticals Ltd.

25 Sep 2025

835.05

-0.31%

Alembic Pharma Gets USFDA Nod For Generic Drug To Treat Depression, Anxiety

NDTV Profit

The final approval by the US Food & Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) of Paroxetine extended-release tablets of strengths 25 mg and 37.5 mg, Alembic Pharmaceuticals said in a regulatory filing.

Alembic Pharmaceuticals Ltd. is trading below all available SMAs

Alembic Pharmaceuticals Ltd.

19 Aug 2025

835.05

-0.31%

Alembic Pharma shares rise 2% on pulmonary hypertension drug approval

Business Standard

Alembic Pharma shares rose 2.3 per cent on Tuesday, after the company received US Food & Drug Administration (USFDA) final approval for its Abbreviated New Drug Application (ANDA) Macitentan Tablets